People often worry about sleeplessness—which is
exactly what drug companies encourage. Using their influence, five pharmaceutical companies managed to
establish a National Sleep Foundation that labeled sleeping problems as “public
health crisis” and a “national emergency.”
The primary pharmaceutical sponsors of this so-called non-profit organization, founded
in 1990, all manufacture sleeping pills.
Naturally, the pharmaceutical companies launched ad
campaigns to deal with this “public health crisis.” Their campaigns were wildly
successful: between 2001 and 2005 sleeping pill prescriptions grew by 55
percent, to 45.5 million; by 2011, the number was 60 million. By 2012, 4% of our population was taking
sleeping pills.
But here’s the thing: Sleeping pills, such as Ambien and
Lunesta aren’t even especially helpful. In a 2007 study financed by the
National Institutes of Health, these “hypnotics” reduced the average time to
fall asleep by 12.8 minutes and increased total sleep time by only 11.4
minutes. One drug, Sonata, did not extend sleeping time at
all. (Test subjects slept six hours and 20 minutes whether they had taken a
sleeping pill or a placebo.) Such a paltry benefit doesn’t begin to compensate
for the dangers of sleeping pills—which are considerable.
In a 2012 study reported in the British Medical Journal researchers compared
medical records of 10,529 people who used hypnotic drugs with 23,671 who used
none during the same period. They found that patients taking the sleeping pills
on a regular basis were nearly five times as likely as non-users to die over a
period of two and a half years. Heavy users were more likely to develop cancer.
Previous studies performed in Norway, Canada, and Sweden had also found a link
between sleeping pills and increased risk of death. The Swedish study, which
followed people for 20 years, found that regular users of hypnotics were 5.6
times as likely to die during the study period, while women were twice as
likely to die.
Best to count sheep, I think.
Next week: A sleep survey
For an introduction to this blog, see I Just Say No; for a list of blog topics, click the Topics tab.
No comments:
Post a Comment